Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

December 2020

Volume 18Issue 6p423-514, e643-e770

Select all

Download started.
Ok

Please select at least one article in order to proceed.

The 2020 nccRCC Immunotherapy Issue

James J. Hsieh

Published in issue: December 2020

p423-424

Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?

Jacob J. Adashek,
Jarred P. Reed,
Ankita Tandon,
...
Michael Freeman,
Robert A. Figlin,
Jun Gong

Published online: May 10, 2020

p425-428

Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non–Clear Cell Renal Cell Carcinoma

Ruby Gupta,
Moshe Chaim Ornstein,
Hong Li,
...
Dendra Von Merveldt,
Hans J. Hammers,
Brian I. Rini

Published online: December 04, 2019

p429-435

Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer

Evan Y. Yu,
Michael L. Hancock,
William Aronson,
...
Ryan Taylor,
Patrick C. Hardigan,
Robert H. Getzenberg

Published online: March 27, 2020

p436-443

Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial

Clément Dumont,
Giulia Baciarello,
Pierre-Olivier Bosset,
...
Alberto Bossi,
Soazig Nenan,
Karim Fizazi

Published online: April 07, 2020

p444-451

Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma

Joaquim Bellmunt Molins,
Jesús García-Donas Jiménez,
Begoña P. Valderrama,
...
Javier Puente Vázquez,
Rafael Morales-Barrera,
Albert Font Pous

Published online: May 11, 2020

p452-460

Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

Nicholas J. Vogelzang,
Mark R. Olsen,
Joshua J. McFarlane,
...
M. Brent McHenry,
Jennifer L. Johansen,
Scott S. Tykodi

Published online: May 15, 2020

p461-468.e3

Open Access

Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

Joshua J. McFarlane,
Mark D. Kochenderfer,
Mark R. Olsen,
...
M. Brent McHenry,
Jennifer L. Johansen,
Nicholas J. Vogelzang

Published online: June 13, 2020

p469-476.e4

Open Access

Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

Maria Giuseppa Vitale,
Stefania Pipitone,
Marta Venturelli,
...
Giovanna Vitale,
Pasquale Mighali,
Roberto Sabbatini

Published online: May 20, 2020

p477-488

A Nationwide Persistent Underutilization of Adjuvant Radiotherapy in North American Prostate Cancer Patients

Nikola Rakic,
Akshay Sood,
Deepansh Dalela,
...
James Peabody,
Mani Menon,
Firas Abdollah

Published online: May 16, 2020

p489-499.e6

Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival

Jaleh Fallah,
Claudia Marcela Diaz-Montero,
Patricia Rayman,
...
Brian Rini,
Moshe C. Ornstein,
Petros Grivas

Published online: March 18, 2020

p500-508

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma

Landon C. Brown,
Jason Zhu,
Matthew K. Labriola,
...
Daniel J. George,
Michael R. Harrison,
Tian Zhang

Published online: April 10, 2020

p509-513

Editorial Board

Published in issue: December 2020

December 2020

Editor's Preview

The 2020 nccRCC Immunotherapy Issue

Review

Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?

Original Studies

Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non–Clear Cell Renal Cell Carcinoma

Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer

Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial

Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma

Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

A Nationwide Persistent Underutilization of Adjuvant Radiotherapy in North American Prostate Cancer Patients

Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival

Case Series

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma

Available Exclusively Online at www.clinical-genitourinary-cancer.com

Factors Associated With Receipt of Partial Nephrectomy or Minimally Invasive Surgery for Patients With Clinical T1a and T1b Renal Masses: Implications for Regionalization of Care

Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non–muscle-invasive Bladder Cancer

Low-Dose Enzalutamide in Late-Elderly Patients (≥ 75 Years Old) Presenting With Metastatic Castration-Resistant Prostate Cancer

The Impact of 3D Digital Reconstruction on the Surgical Planning of Partial Nephrectomy: A Case-control Study. Still Time for a Novel Surgical Trend?

Characterization of Brain Metastases in Urothelial Cancers

Negative Biopsy Histology in Men With PI-RADS Score 5 in Daily Clinical Practice: Incidence of Granulomatous Prostatitis

Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review

TFE3 Gene Rearrangement in Perivascular Epithelioid Cell Neoplasm (PEComa) of the Genitourinary Tract

The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?

Survival Outcomes for Metastatic Prostate Cancer Patients Treated With Radical Prostatectomy or Radiation Therapy: A SEER-based Study

Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis

Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma

Active Surveillance for Intermediate-Risk Prostate Cancer: Systematic Review and Meta-analysis of Current Protocols and Outcomes

Chronic Kidney Disease After Partial Nephrectomy in Patients With Preoperative Inconspicuous Renal Function – Curiosity or Relevant Issue?

National Trends and Impact of Regionalization of Radical Cystectomy on Survival Outcomes in Patients with Muscle Invasive Bladder Cancer

Frontmatter

Editorial Board

Table of Contents